Drug Profile
PF 06835919
Alternative Names: PF-06835919Latest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action Fructokinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 22 Jun 2022 Phase-II clinical trials in Non-alcoholic fatty liver disease in Netherlands (PO) (EudraCT2021-006677-26)
- 28 Jul 2021 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Belgium (PO) (Pfizer pipeline, July 2021)
- 28 Jul 2021 Discontinued - Phase-II for Non-alcoholic fatty liver disease in Canada, USA (PO) (Pfizer pipeline, July 2021)